XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Temporary equity, beginning balance (in shares) at Dec. 31, 2020 127,082,605        
Temporary equity, beginning balance at Dec. 31, 2020 $ 387,707        
Redeemable Convertible Preferred Stock          
Issuance of Series F redeemable convertible preferred stock, net of issuance costs (in shares) 328,026        
Issuance of Series F redeemable convertible preferred stock, net of issuance costs $ 3,000        
Temporary equity, ending balance (in shares) at Mar. 31, 2021 127,410,631        
Temporary equity, ending balance at Mar. 31, 2021 $ 390,707        
Beginning balance (in shares) at Dec. 31, 2020   24,289,906      
Beginning balance at Dec. 31, 2020 (211,329) $ 2 $ 8,766 $ 591 $ (220,688)
Stockholders' Equity          
Issuance of common stock upon exercise of stock options, including early exercised options, and vesting of restricted stock units (in shares)   706,948      
Issuance of common stock upon exercise of stock options, including early exercised options, and vesting of restricted stock units 1,104   1,104    
Stock-based compensation expense 1,522   1,522    
Other comprehensive income (32)     (32)  
Net loss (7,770)       (7,770)
Ending balance (in shares) at Mar. 31, 2021   24,996,854      
Ending balance at Mar. 31, 2021 $ (216,505) $ 2 11,392 559 (228,458)
Temporary equity, beginning balance (in shares) at Dec. 31, 2021 0        
Temporary equity, beginning balance at Dec. 31, 2021 $ 0        
Temporary equity, ending balance (in shares) at Mar. 31, 2022 0        
Temporary equity, ending balance at Mar. 31, 2022 $ 0        
Beginning balance (in shares) at Dec. 31, 2021   164,239,555      
Beginning balance at Dec. 31, 2021 480,328 $ 16 739,503 253 (259,444)
Stockholders' Equity          
Issuance of common stock upon exercise of stock options, including early exercised options, and vesting of restricted stock units (in shares)   1,696,601      
Issuance of common stock upon exercise of stock options, including early exercised options, and vesting of restricted stock units 2,678 $ 1 2,677    
Issuance of common stock through Employee Stock Purchase Plan (in shares)   202,213      
Issuance of common stock through Employee Stock Purchase Plan 1,882   1,882    
Stock-based compensation expense 9,921   9,921    
Other comprehensive income 4     4  
Net loss (23,310)       (23,310)
Ending balance (in shares) at Mar. 31, 2022   166,138,369      
Ending balance at Mar. 31, 2022 $ 471,503 $ 17 $ 753,983 $ 257 $ (282,754)